Medtronic Stock Price, News & Analysis

Medtronic (NYSE:MDT) reported strong Q1 FY2026 results with revenue reaching $8.6 billion, an 8.4% increase as reported and 4.8% organic growth. The company achieved GAAP diluted EPS of $0.81 (up 1%) and non-GAAP diluted EPS of $1.26 (up 2%).

Key performance highlights include Cardiac Ablation Solutions revenue surge of nearly 50% (72% in US) driven by pulsed field ablation products. The Cardiovascular Portfolio led growth with a 7.0% organic increase, while the Diabetes business showed strong performance with 7.9% organic growth.

Looking ahead, Medtronic raised its FY26 EPS guidance to $5.60-$5.66 (previously $5.50-$5.60) while maintaining organic revenue growth guidance of approximately 5%. The company expects reduced tariff impact of approximately $185 million, down from the previous estimate of $200-350 million.

Medtronic (NYSE:MDT) has declared a quarterly cash dividend of $0.71 per ordinary share for the second quarter of fiscal year 2026. The dividend will be paid on October 17, 2025, to shareholders of record as of September 26, 2025.

This declaration maintains the dividend level announced in May 2025. As a member of the S&P 500 Dividend Aristocrats index, Medtronic has consistently increased its annual dividend for 48 consecutive years. The company operates globally with 95,000+ employees across 150+ countries, focusing on healthcare technology solutions that address 70 different health conditions.

Medtronic (NYSE:MDT), the global healthcare technology leader, has scheduled its fiscal year 2026 first quarter financial results announcement for Tuesday, August 19, 2025. The results will cover the period ending July 25, 2025.

The company will release its financial summary at 5:45 a.m. CDT, followed by a video webcast at 7:00 a.m. CDT. Medtronic has also announced the reporting dates for the remaining quarters of FY2026: November 18, 2025 (Q2), February 17, 2026 (Q3), and May 20, 2026 (Q4).

Medtronic (NYSE:MDT) has secured CE Mark approval for expanded indications of its MiniMed™ 780G system, now authorized for use in children as young as 2 years old, pregnant women, and type 2 diabetes patients in Europe.

Clinical data showed significant benefits across all new indications: The LENNY trial demonstrated a 0.6% lower HbA1C and 9.9% higher time in range in children aged 2-6 years. For pregnant women, the system achieved an average Pregnancy Time in Range of 66.5%. In type 2 diabetes patients, trials showed a 0.7% reduction in HbA1c and increased time in range to 80%.

The company is currently seeking FDA approval for type 2 diabetes indication in the U.S. and conducting clinical trials for use in young children.

Medtronic (NYSE:MDT) has appointed Chad Spooner as Chief Financial Officer of MiniMed, effective July 14, 2025, ahead of its planned separation into an independent public company. Spooner brings over 25 years of financial leadership experience, most recently serving as CFO at BIC.

The appointment comes as Medtronic prepares to spin off its diabetes business under the MiniMed name within 18 months of the initial announcement. MiniMed focuses on transforming diabetes care for patients with type 1 and type 2 diabetes requiring daily insulin injections. The separation will be executed through a series of capital markets transactions, subject to customary conditions and legal requirements.

Medtronic (NYSE:MDT) has appointed Dr. Joon Lee, CEO of Emory Healthcare, to its Board of Directors as an independent director, effective June 18, 2025. Dr. Lee, who will serve on the Science and Technology Committee and Compensation and Talent Committee, brings over 25 years of healthcare leadership experience.

Currently leading Emory Healthcare's $7.7B healthcare system with 12 hospitals and 29,000+ employees, Dr. Lee previously held executive positions at UPMC, including Executive VP and President of Physician Services. He also served as CMO of UPMC Insurance Services, managing a $13B health insurance division. His expertise spans interventional cardiology, clinical research, and healthcare technology.

Medtronic (NYSE: MDT) has announced that its planned spinoff diabetes business will be named MiniMed, reviving the original name of the company acquired by Medtronic in 2001. The separation is expected to complete within 18 months, subject to various conditions. MiniMed, to be based in Northridge, California, will operate with over 8,000 employees focused on diabetes care innovation. The company's mission centers on making diabetes more manageable through technology, exemplified by products like the MiniMed 780G system. Que Dallara, current EVP and President of Medtronic Diabetes, will serve as CEO of the new standalone company. The separation is expected to occur through capital markets transactions, which may include a spin-off, split-off, offering, or combination thereof. The company's legacy dates back to 1983 when Alfred E. Mann founded the original MiniMed, establishing a 40-year history in transforming diabetes care.

Medtronic (NYSE: MDT) announced its participation in Bernstein's 41st Strategic Decisions Conference on May 29, 2025. Chairman and CEO Geoff Martha will deliver a presentation at 11:00 a.m. EDT, followed by a Q&A session with CFO Thierry Piéton. The event will be webcast live and archived on Medtronic's investor relations website.

Medtronic, headquartered in Galway, Ireland, is a global healthcare technology leader with 95,000+ employees across 150+ countries. The company develops technologies and therapies for 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems, serving two patients every second worldwide.

Medtronic (MDT) reported strong Q4 FY25 results with revenue of $8.9 billion, up 5.4% organic. Q4 GAAP EPS increased 67% to $0.82, while non-GAAP EPS rose 11% to $1.62. For FY25, revenue reached $33.5 billion, growing 4.9% organic, with GAAP EPS of $3.61 (up 31%) and non-GAAP EPS of $5.49 (up 6%). The company announced three major developments: 1) Plans to separate its Diabetes business into a standalone public company within 18 months, 2) A dividend increase to $0.71 per share (marking the 48th consecutive annual increase), and 3) FY26 guidance projecting ~5% organic revenue growth and non-GAAP EPS of $5.50-$5.60. Strong performance was noted across key franchises, particularly in Cardiac Ablation Solutions which grew nearly 30% in Q4.